Quince Therapeutics, Inc.

Equities

QNCX

US22053A1079

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-14 pm EDT			5-day change	1st Jan Change
0.91 ^USD	-1.05%		-1.09%	-13.33%

May. 13	Quince Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 01	Quince Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

QUINCE THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)

March 28, 2023 at 05:06 pm EDT

ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Departure of Director

On March 27, 2023, Philip Low. Ph.D., a member of the Board of Directors (the "Board") of Quince Therapeutics, Inc. (the "Company"), tendered his resignation from the Board, effective immediately (the "Departure Date"). Dr. Low's resignation from the Board was not a result of any disagreement with the Company, its Board or management.

--------------------------------------------------------------------------------

Latest news about Quince Therapeutics, Inc.

Quince Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13	CI
Quince Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Transcript : Quince Therapeutics, Inc. - Special Call	Mar. 26
North American Morning Briefing : Markets Steady -2-	Mar. 26	DJ
Quince Therapeutics, Inc. Launches Scientific Advisory Board	Feb. 22	CI
Quince Therapeutics, Inc. Appoints Rajiv Patni to Its Board of Directors	Feb. 15	CI
North American Morning Briefing : All Eyes on -2-	Nov. 21	DJ
Quince Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Quince Therapeutics, Inc. Appoints Brendan Hannah to the Position of Chief Operating Officer	23-10-26	CI
Quince Therapeutics, Inc. Appoints Luca Benatti as Director	23-10-23	CI
Quince Therapeutics, Inc. acquired EryDel S.p.A	23-10-22	CI
Quince Says US FDA Lifts Partial Clinical Hold on EryDel's Treatment for Ataxia-Telangiectasia	23-09-28	MT
Quince Therapeutics to Advance Study of EryDex as FDA Lifts Application Hold	23-09-28	DJ
Quince Therapeutics, Inc. Announces That U.S. Food and Drug Administration Lifts the Partial Clinical Hold on Erydel S.P. A's Investigational New Drug Application for Its Lead Phase 3 Asset, Erydex	23-09-28	CI
Quince Therapeutics Appoints Charles S. Ryan as President	23-09-06	CI
Insider Buy: Quince Therapeutics	23-08-11	MT
Quince Therapeutics, Inc. Announces the Departure of Karen Smith as Chief Medical Officer, Effective September 1, 2023	23-08-10	CI
Quince Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Sector Update: Health Care Stocks Declining Late Monday	23-07-24	MT
Sector Update: Health Care Stocks Easing Monday Afternoon	23-07-24	MT
Quince Therapeutics to Acquire EryDel in All-Stock Deal	23-07-24	MT
Quince Therapeutics, Inc. Announces Board and Executive Changes	23-07-24	CI
Quince Therapeutics, Inc. agreed to acquire EryDel S.p.A. for approximately $510 million.	23-07-23	CI
Quince Therapeutics Shares Rise Pre-Bell After Echo Lake Capital Raises Acquisition Offer	23-07-13	MT
Transcript : Quince Therapeutics, Inc. - Shareholder/Analyst Call	23-05-24

Chart Quince Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Quince Therapeutics, Inc. is a late-stage biotechnology company. The Company is engaged in unlocking the patientâs own biology to deliver life-changing therapeutics to those living with rare diseases. Its proprietary autologous intracellular drug encapsulation (AIDE) technology platform is a drug/device combination that uses an automated process designed to encapsulate a drug into the patientâs own red blood cells. The Companyâs Phase III lead asset, EryDex, leverages its AIDE technology to encapsulate dexamethasone sodium phosphate (DSP) into a patientâs own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, Ataxia-Telangiectasia (A-T). Its AIDE technology is designed to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules, as well as biologics.

Sector

Biotechnology & Medical Research

Calendar

2024-06-05 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
QUINCE THERAPEUTICS, INC.	-13.33%	39.33M
MODERNA, INC.	+29.03%	49.18B
IQVIA HOLDINGS INC.	-0.10%	42.11B
LONZA GROUP AG	+43.45%	40.37B
CELLTRION, INC.	-5.26%	28.85B
ICON PUBLIC LIMITED COMPANY	+11.48%	26.09B
ALNYLAM PHARMACEUTICALS, INC.	-22.74%	18.71B
BIO-TECHNE CORPORATION	+9.06%	13.26B
MEDPACE HOLDINGS, INC.	+30.01%	12.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.51%	11.99B

Other Biotechnology & Medical Research